Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY January 2024 slide deck - over 120 panc pts studied

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Mar 23, 2024 9:23pm

140 Views

Post# 35949170

RE:RE:RE:ONCY January 2024 slide deck - over 120 panc pts studied

The evolving metastatic pancreatic cancer arm of the Goblet Phase 2 study involving pelareorep + atezolizumsb + n-paclitaxel had the following still maturing findings at the time of the trial cut-off date : an overall response rate (ORR) of 62% (54% confirmed by two or more scans), a Disease Control Rate (DCR) of 85%, 7.2 months of median progression-free survival (mPFS), interim median overall survival (imOS) of 10.6 months, and expansion of both pre-existing and new T-cell clones.

https://www.prnewswire.com/

<< Previous

Bullboard Posts

Next >>

These cold weather stocks are looking to heat up for winter